By examining both technical and fundamental indicators, you can assess how market fluctuations impact the stock prices of Vigil Neuroscience and Monte. This analysis can help determine if combining these stocks in a portfolio might reduce market risk. Additionally, you might consider a pair trading strategy by taking a long position in Monte and a short position in Vigil Neuroscience. For more details, explore our [pair correlation module](#) to understand their relationship better.
Let's dive into Vigil's asset utilization. Currently, Vigil Neuroscience has a negative asset utilization rate of -0.49%, meaning it loses about $0.004938 for every dollar of assets. This suggests that the company isn't using its assets efficiently, highlighting a need for improved operational effectiveness.
Main Points
Considering Vigil Neuroscience's current stock price hovering around
7.89 and a Wall Street target price of
10.81, there appears to be potential upside for investors willing to navigate the inherent risks of the biotechnology sector. However, with a significant loss of
51.2M from operating activities, caution is advised as the company works towards financial stability.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Vigil or Tyra is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Vigil Neuroscience's Liquidity
Vigil Neuroscience
financial leverage refers to using borrowed capital as a funding source to finance Vigil Neuroscience ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Vigil Neuroscience financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Vigil Neuroscience's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Vigil Neuroscience's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Vigil Neuroscience's total debt and its cash.
Correlation Between Vigil and Tyra Biosciences
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Vigil Neuroscience together with similar or unrelated positions with a negative correlation. For example, you can also add Tyra Biosciences to your portfolio. If Tyra Biosciences is not perfectly correlated to Vigil Neuroscience it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Vigil Neuroscience, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Vigil Neuroscience and Tyra Biosciences in your portfolio? Please note if you are using this as a pair-trade strategy between Vigil Neuroscience and Tyra Biosciences, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between VIGL and TYRA for more information.
What is driving Vigil Neuroscience Investor Appetite?
Total Debt Breakdown
Let me now go over Vigil Neuroscience total debt. Based on the latest financial disclosure, Vigil Neuroscience has a Total Debt of 12.95
M. This is 99.53% lower than that of the Biotechnology sector and 96.01% lower than that of the
Health Care industry. The total debt for all United States stocks is 99.76% higher than that of Vigil Neuroscience.
As for Monte Rosa we see total debt of 42.72
M, which is 86.85% lower than that of the Health Care
| VIGL | 12.95 Million | 3.4 |
| Sector | 324.78 Million | 85.37 |
| GLUE | 42.72 Million | 11.23 |
Success is not final, failure is not fatal: It is the courage to continue that counts, said Winston Churchill, a sentiment that resonates with Vigil Neuroscience as it navigates the challenging waters of the biotechnology sector. With a current ratio of 21.35X, the company demonstrates robust liquidity, suggesting it is well-positioned to meet its short-term obligations. Despite reporting losses with an EPS estimate of -1.94 for the current year, Vigil's strategic focus on developing treatments for neurodegenerative diseases could pave the way for future growth. The company's lead candidate, VGL101, is in a Phase 2 trial, offering potential upside for investors willing to embrace the inherent risks of biotech innovation. As Vigil Neuroscience and Monte Rosa explore strategic paths forward, investors will be keenly watching for any developments that could impact the stock's trajectory..
Will price continue to rise in June 2025?
Vigil Neuroscience's stock has recently seen a dramatic increase in volatility, with its variance jumping over 920.07. This spike has caught the eye of investors and analysts, indicating a surge in trading activity, possibly due to new developments or market speculation. As we approach June 2025, the big question is whether this momentum will continue and drive further price gains. Investors should keep a close watch on upcoming announcements or financial reports from Vigil Neuroscience, as these could offer valuable insights into the company's future performance and help assess the likelihood of the current trend persisting. The stock's heightened volatility underscores the importance of understanding market trends, as it can affect share prices and influence investors to adjust their portfolios in response to market conditions.Vigil Neuroscience is carving out a promising niche in the biotech sector, focusing on innovative treatments for neurodegenerative diseases.
Despite a modest market downturn, the stock's gradual ascent suggests resilience and potential. With a strong buy consensus from analysts, including
6 strong buy recommendations, the company is clearly on the radar of investors looking for promising opportunities. Vigil's lead candidate, VGL101, is advancing through Phase 2 trials, offering a beacon of hope for those affected by rare neurological conditions. While the market can be unpredictable, the potential upside price of
38.36 underscores the optimism surrounding Vigil's future prospects. For investors seeking exposure to cutting-edge biotech advancements, Vigil Neuroscience might be worth a closer look..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Vigil Neuroscience. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
